Results 91 to 100 of about 6,944 (246)

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review

Frontiers in Clinical Diabetes and Healthcare
Traditionally, Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a pivotal class of drug, mimics the actions of endogenous Glucagon-like peptide-1, which have been found to be remarkable in the treatment of type 2 diabetes alongside other ...
Bisma Fatima Hammad, Nimrah Zafar, Muneeb Ullah, Syeda Jazilah Faisal, Fizzah Iftikhar, Haadia Waheed, Muhammad Waleed Muzaffar, Khadija Ahmed, Faz Ashraf, Komal Zahid, Maimoona Akhtar, Mohammed Mahmmoud Fadelallah Eljack   +11 more
doaj   +1 more source

Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach

Internal Medicine Journal, EarlyView.
Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich, W. P. Abhayaratna, R. Audehm, E. I. Ekinci, R. J. MacIsaac, A. J. Nelson, A. Sharma, C. Pollock   +7 more
wiley   +1 more source

Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China

Diabetes, Metabolic Syndrome and Obesity
Zhen Ruan,1,* Xianwen Chen,1,* Menghuan Song,1 Ruxu Jia,2 Hang Luo,3 Carolina Oi Lam Ung,1,4,5 Hao Hu1,4,5 1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR,
Ruan Z, Chen X, Song M, Jia R, Luo H, Ung COL, Hu H   +6 more
doaj  

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity

Journal of Obesity
Obesity is considered the leading public health problem in the medical sector. The phenotype includes overweight conditions that lead to several other comorbidities that drastically decrease health.
Ibrahim Abdullah bin Ahmed
doaj   +1 more source

Glucometabolic Outcomes of GLP-1RA-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

, 2023
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia C. Palmer, Patrizia Natale, Giovanni FM Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +10 more
openalex   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

Journal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, Takehiro Kato, Yukio Horikawa, Katsumi Iizuka, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yutaka Seino, Shin Tsunekawa, Daisuke Yabe   +17 more
wiley   +1 more source

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy [PDF]

, 2020
Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno   +5 more
openalex   +1 more source

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial [PDF]

, 2021
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Lage, Charlie Scott, George L. Bakris, the FIDELIO‐DKD Investigators   +12 more
openalex   +1 more source